Science & Technology
Science and Technology
Science and Technology
Tue, December 1, 2009 The Lifesaving Capability of ValiMed(TM) MVS to Be Demonstrated at the ASHP Conference
TUCSON, AZ--(Marketwire - December 1, 2009) - CDEX Inc. (
"The ASHP Mid-Year meeting presents an opportunity for CDEX to inform the Directors of Pharmacy from the nation's hospitals about the benefits of incorporating the ValiMed MVS into their pharmacy workflow," said Greg Firmbach, CDEX Senior VP. "ValiMed MVS is increasing overall patient safety as a final check in the prevention of human error in the compounding of high-risk medications and as the central validation point for the disposal of narcotics as part of a narcotic diversion prevention program."
Worldwide studies continue to show that human errors in the compounding of high-risk medications occur frequently and result in permanent harm to patients throughout the world and that the diversion of medical narcotics is a continuing problem. ValiMed MVS is a technological safety net that provides protection for patients, pharmacists and hospitals.
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at [ mphilips@cdex-inc.com ].
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
